

Supplemental Tables. Synergy of clofazimine, clarithromycin, amikacin, dapson, rifampin, and tigecycline with various antibiotics against MDR-*M. abscessus* strains isolated from cystic fibrosis patients.

	CLA	SXT	CIP	MXF	FOX	AMI	TGC	LZD	IMI	FEP	AUG	AXO	MIN	TOB
Strain 11	>16	>8/152	>4	>8	64	32	4	>32	16	>32	>64/32	>64	>8	>16
CFZ (0.5)	<1	<0.25/4.75	<0.12	<0.25	<4	<1	<0.015	<1	<2	<1	<2/1	<4	<1	<1
Strain 12	>16	>8/152	>4	>8	16	32	1	>32	16	16	32/16	>64	8	>16
CFZ (0.5)	<1	<0.25/4.75	<0.12	<0.25	<4	<1	<0.015	<1	<2	<1	<2/1	<4	<1	<1
Strain 13	8	8/152	>4	>8	64	32	2	>32	16	32	>64/32	>64	8	>16
CFZ (0.5)	<1	<0.25/4.75	<0.12	<0.25	<4	<1	<0.015	<1	<2	<1	<2/1	<4	<1	<1
Strain 14	4	>8/152	>4	>8	128	16	4	>32	32	>32	>64/32	>64	>8	>16
CFZ (0.5)	<1	<0.25/4.75	<0.12	<0.25	<4	<1	<0.015	<1	<2	<1	<2/1	<4	<1	<1
Strain 16	4	>8/152	4	8	32	16	0.5	16	16	32	>64/32	>64	>8	>16
CFZ (0.5)	<1	<0.25/4.75	<0.12	<0.25	<4	<1	<0.015	<1	<2	<1	<2/1	<4	<1	<1
Strain 17	>16	8/152	4	8	32	16	1	16	4	16	64/32	>64	>8	>16
CFZ (0.5)	<1	<0.25/4.75	<0.12	<0.25	<4	<1	<0.015	<1	<2	<1	<2/1	<4	<1	<1
Strain 19	>16	>8/152	>4	>8	128	32	>4	>32	64	>32	>64/32	>64	>8	>16
CFZ (0.5)	<1	<0.25/4.75	<0.12	<0.25	<4	<1	<0.015	<1	<2	<1	<2/1	<4	<1	<1
Strain 25	>16	>8/152	>4	>8	64	32	2	>32	16	>32	>64/32	>64	>8	>16
CFZ (0.5)	<1	<0.25/4.75	<0.12	<0.25	<4	<1	<0.015	<1	<2	<1	<2/1	<4	<1	<1
Strain 26	16	>8/152	>4	>8	32	32	1	>32	8	>32	>64/32	>64	>8	>16
CFZ (0.5)	<1	<0.25/4.75	<0.12	<0.25	<4	<1	<0.015	<1	<2	<1	<2/1	<4	<1	<1

Table S1. Clofazimine synergy.

Table S2. Amikacin synergy.

	CLA	SXT	CIP	MXF	FOX	TGC	LZD	IMI	FEP	AUG	AXO	MIN	TOB
Strain 11	>16	>8/152	>4	>8	64	4	>32	16	>32	>64/32	>64	>8	>16
AMI (8)	<1	<0.25/4.75	<0.12	<0.25	<4	<0.015	<1	<2	<1	<2/1	<4	<1	<1
Strain 12	>16	>8/152	>4	>8	16	1	>32	16	16	32/16	>64	8	>16
AMI (8)	0.06	"0.25/4.75"	0.12	0.25	4	0.015	1	2	1	"2/1"	4	1	1
Strain 13	8	8/152	>4	>8	64	2	>32	16	32	>64/32	>64	8	>16
AMI (8)	0.06	"0.25/4.75"	0.12	0.25	4	<0.015	1	2	1	"2/1"	4	1	1
Strain 14	4	>8/152	>4	>8	128	4	>32	32	>32	>64/32	>64	>8	>16
AMI (8)	0.06	"0.25/4.75"	0.12	0.25	4	0.015	1	2	1	"2/1"	4	1	1
Strain 16	4	>8/152	4	8	32	0.5	16	16	32	>64/32	>64	>8	>16
AMI (8)	0.06	"0.25/4.75"	0.12	0.25	4	0.015	1	2	1	"2/1"	4	1	1
Strain 17	>16	8/152	4	8	32	1	16	4	16	64/32	>64	>8	>16
AMI (8)	<0.06	"2/38"	4	>8	4	<0.015	<1	<2	<1	>64/32	<4	<1	<1
Strain 19	>16	>8/152	>4	>8	128	>4	>32	64	>32	>64/32	>64	>8	>16
AMI (8)	0.06	"0.25/4.75"	0.12	0.25	4	0.015	1	2	1	"2/1"	4	1	1
Strain 25	>16	>8/152	>4	>8	64	2	>32	16	>32	>64/32	>64	>8	>16
AMI (8)	0.06	"0.25/4.75"	0.12	0.25	4	0.015	1	2	1	"2/1"	4	1	1
Strain 26	16	>8/152	>4	>8	32	1	>32	8	>32	>64/32	>64	>8	>16

Table S3. Clarithromycin synergy.

	SXT	CIP	MXF	FOX	AMI	TGC	LZD	IMI	FEP	AUG	AXO	MIN	TOB
Strain 11	>8/152	>4	>8	64	32	4	>32	16	>32	>64/32	>64	>8	>16
CLA(4)	<0.25/4.75	<0.12	<0.25	<4	<1	<0.015	<1	<2	<1	<2/1	<4	<1	<1
Strain 12	>8/152	>4	>8	16	32	1	>32	16	16	32/16	>64	8	>16
CLA(4)	"0.25/4.75"	0.12	0.25	4	1	0.015	1	2	1	"2/1"	4	1	1
Strain 13	8/152	>4	>8	64	32	2	>32	16	32	>64/32	>64	8	>16
CLA(4)	"0.25/4.75"	0.12	0.25	4	1	0.015	1	2	1	"2/1"	4	1	1
Strain 14	>8/152	>4	>8	128	16	4	>32	32	>32	>64/32	>64	>8	>16
CLA(4)	"0.25/4.75"	0.12	0.25	4	1	0.015	1	2	1	"2/1"	4	1	1
Strain 16	>8/152	4	8	32	16	0.5	16	16	32	>64/32	>64	>8	>16
CLA(4)	"0.25/4.75"	0.12	0.25	4	1	0.015	1	2	1	"2/1"	4	1	1
Strain 17	8/152	4	8	32	16	1	16	4	16	64/32	>64	>8	>16
CLA(4)	"2/38"	0.25	>9	4	<1	<0.015	<1	<2	<1	>64/32	<4	<1	<1
Strain 19	>8/152	>4	>8	128	32	>4	>32	64	>32	>64/32	>64	>8	>16
CLA(4)	"0.25/4.75"	0.12	0.25	4	1	0.015	1	2	1	"2/1"	4	1	1
Strain 25	>8/152	>4	>8	64	32	2	>32	16	>32	>64/32	>64	>8	>16
CLA(4)	"0.25/4.75"	0.12	0.25	4	1	0.015	1	2	1	"2/1"	4	1	1
Strain 26	>8/152	>4	>8	32	32	1	>32	8	>32	>64/32	>64	>8	>16
CLA(4)	"0.25/4.75"	0.12	0.25	4	1	0.015	1	2	1	"2/1"	4	1	1

Table S4. Dapsone synergy.

	CLA	SXT	CIP	MXF	FOX	AMI	TGC	LZD	IMI	FEP	AUG	AXO	MIN	TOB
Strain 11	>16	>8/152	>4	>8	64	32	4	>32	16	>32	>64/32	>64	>8	>16
DAP(0.5)	2	8/152	4	4	64	4	1	32	64	>32	>64/32	>64	>8	8
Strain 12	>16	>8/152	>4	>8	16	32	1	>32	16	16	32/16	>64	8	>16
DAP(0.5)	>16	>8/152	>4	>8	>128	>64	>4	>32	>64	>32	>64/32	>64	>8	>16
Strain 13	8	8/152	>4	>8	64	32	2	>32	16	32	>64/32	>64	8	>16
DAP(0.5)	2	>8/152	1	8	64	4	0.5	>32	>64	>32	>64/32	>64	>8	>16
Strain 14	4	>8/152	>4	>8	128	16	4	>32	32	>32	>64/32	>64	>8	>16
DAP(0.5)	<0.06	"0.25/4.75"	0.12	0.25	4	1	0.015	1	2	1	"2/1"	4	1	1
Strain 16	4	>8/152	4	8	32	16	0.5	16	16	32	>64/32	>64	>8	>16
DAP(0.5)	0.06	"0.25/4.75"	0.12	0.25	4	1	0.015	1	2	1	"2/1"	4	1	1
Strain 17	>16	8/152	4	8	32	16	1	16	4	16	64/32	>64	>8	>16
DAP(0.5)	ND	"1/19"	2	1	16	2	0.5	32	8	16	64/32	>64	>8	16
Strain 19	>16	>8/152	>4	>8	128	32	>4	>32	64	>32	>64/32	>64	>8	>16
DAP(0.5)	<0.06	"0.25/4.75"	0.12	0.25	128	8	<0.015	32	2	1	"2/1"	4	1	1
Strain 25	>16	>8/152	>4	>8	64	32	2	>32	16	>32	>64/32	>64	>8	>16
DAP(0.5)	1	"4/76"	2	4	32	4	2	32	8	16	>64/32	>64	>8	16
Strain 26	16	>8/152	>4	>8	32	32	1	>32	8	>32	>64/32	>64	>8	>16
DAP(0.5)	0.5	>8/152	>4	4	64	16	1	ND	32	>32	>64/32	>64	>8	>16

Table S5. Rifampin synergy.

	CLA	SXT	CIP	MXF	FOX	AMI	TGC	LZD	IMI	FEP	AUG	AXO	MIN	TOB
Strain 11	>16	>8/152	>4	>8	64	32	4	>32	16	>32	>64/32	>64	>8	>16
RIF(1)	4	8/152	4	8	64	2	1	16	32	32	>64/32	>64	>8	8
Strain 12	>16	>8/152	>4	>8	16	32	1	>32	16	16	32/16	>64	8	>16
RIF(1)	>16	"4/76"	>4	8	128	4	1	4	16	32	64/32	32	>8	4
Strain 13	8	8/152	>4	>8	64	32	2	>32	16	32	>64/32	>64	8	>16
RIF(1)	0.25	8/152	>4	8	64	4	0.5	>32	4	16	>64/32	>64	>8	16
Strain 14	4	>8/152	>4	>8	128	16	4	>32	32	>32	>64/32	>64	>8	>16
RIF(1)	1	>8/152	>4	8	128	4	1	32	32	16	>64/32	>64	>8	16
Strain 16	4	>8/152	4	8	32	16	0.5	16	16	32	>64/32	>64	>8	>16
RIF(1)	0.06	"0.25/4.75"	0.12	0.25	4	1	0.015	1	2	1	"2/1"	4	1	1
Strain 17	>16	8/152	4	8	32	16	1	16	4	16	64/32	>64	>8	>16
RIF(1)	4	"2/38"	2	0.5	32	2	4	16	2	2	16/8	32	8	16
Strain 19	>16	>8/152	>4	>8	128	32	>4	>32	64	>32	>64/32	>64	>8	>16
RIF(1)	2	8/152	>4	>8	128	8	4	32	>64	32	>64/32	>64	>8	16
Strain 25	>16	>8/152	>4	>8	64	32	2	>32	16	>32	>64/32	>64	>8	>16
RIF(1)	1	"4/76"	2	2	64	2	2	32	8	32	>64/32	>64	>8	8
Strain 26	16	>8/152	>4	>8	32	32	1	>32	8	>32	>64/32	>64	>8	>16
RIF(1)	<0.06	>8/152	>4	4	64	16	1	32	16	32	>64/32	>64	>8	>16

Table S6. Tigecycline synergy.

	CLA	SXT	CIP	MXF	FOX	AMI	LZD	IMI	FEP	AUG	AXO	MIN	TOB
Strain 11	>16	>8/152	>4	>8	64	32	>32	16	>32	>64/32	>64	>8	>16
TGC(0.5)	16	"4/76"	>4	>8	>128	>64	>32	>64	>32	>64/32	>64	>8	>16
Strain 12	>16	>8/152	>4	>8	16	32	>32	16	16	32/16	>64	8	>16
TGC(0.5)	>16	>8/152	4	>8	>128	8	32	64	32	64/32	>64	>8	16
Strain 13	8	8/152	>4	>8	64	32	>32	16	32	>64/32	>64	8	>16
TGC(0.5)	0.25	"4/76"	2	8	64	8	32	64	32	>64/32	>64	8	16
Strain 14	4	>8/152	>4	>8	128	16	>32	32	>32	>64/32	>64	>8	>16
TGC(0.5)	1	"4/76"	>4	8	128	8	>32	16	>32	>64/32	>64	>8	16
Strain 16	4	>8/152	4	8	32	16	16	16	32	>64/32	>64	>8	>16
TGC(0.5)	0.06	"0.25/4.75"	0.12	0.25	4	1	1	2	1	"2/1"	4	1	1
Strain 17	>16	8/152	4	8	32	16	16	4	16	64/32	>64	>8	>16
TGC(0.5)	16	".5/9.5"	0.5	4	64	4	>32	>64	16	64/32	64	8	16
Strain 19	>16	>8/152	>4	>8	128	32	>32	64	>32	>64/32	>64	>8	>16
TGC(0.5)	1	"2/38"	2	4	128	8	16	64	>32	>64/32	>64	>8	16
Strain 25	>16	>8/152	>4	>8	64	32	>32	16	>32	>64/32	>64	>8	>16
TGC(0.5)	0.5	"4/76"	2	4	64	4	32	4	16	>64/32	>64	>8	16
Strain 26	16	>8/152	>4	>8	32	32	>32	8	>32	>64/32	>64	>8	>16
TGC(0.5)	0.5	>8/152	>4	>8	64	16	32	64	>32	>64/32	>64	>8	>16

Abbreviations for all Tables: CLA, Clarithromycin; SXT, trimethoprim/sulfamethoxazole; CIP, ciprofloxacin; MXF, moxifloxacin; FOX, ceftiofur; AMI, amikacin; TGC, tigecycline; LZD, linezolid; IMI, imipenem; FEP, cefepime; AUG, augmentin; AXO, ceftriaxone; MIN, minocycline; CFZ, clofazimine; TOB, tobramycin; CFZ, clofazimine; RIF, rifampin; DAP, dapsone. A total of 14 antibiotic combinations were performed using clofazimine, dapsone, and rifampin, and a total of 13 combinations was done using clarithromycin, amikacin, and tigecycline. Static concentrations of the following antibiotics were used in synergy testing in combination with varying concentrations of other drugs: clofazimine, dapsone and tigecycline, 0.5 µg/ml; clarithromycin, 4 µg/ml; rifampin, 1 µg/ml, and amikacin 8 µg/ml.